Cubist Systematic Strategies, LLC Oric Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.26 - $6.75 $3,561 - $5,643	836 Added 15.27%	6,309 $35,000
Q4 2022 Feb 14, 2023	SELL	$2.41 - $5.89 $19,496 - $47,650	-8,090 Reduced 59.65%	5,473 $32,000
Q3 2022 Nov 14, 2022	BUY	$3.15 - $5.24 $463 - $770	147 Added 1.1%	13,563 $43,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.07 $167,894 - $439,633	-62,183 Reduced 82.25%	13,416 $60,000
Q1 2022 May 16, 2022	BUY	$4.54 - $16.1 $343,219 - $1.22 Million	75,599 New	75,599 $404,000
Q4 2021 Feb 14, 2022	SELL	$12.01 - $20.3 $25,761 - $43,543	-2,145 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$15.9 - $25.22 $141,176 - $223,928	-8,879 Reduced 80.54%	2,145 $45,000
Q2 2021 Aug 16, 2021	BUY	$17.37 - $25.34 $168,037 - $245,139	9,674 Added 716.59%	11,024 $195,000
Q1 2021 May 17, 2021	BUY	$23.67 - $36.85 $31,954 - $49,747	1,350 New	1,350 $33,000
Q3 2020 Nov 16, 2020	SELL	$19.5 - $31.26 $206,661 - $331,293	-10,598 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$25.68 - $38.12 $272,156 - $403,995	10,598 New	10,598 $357,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.